Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2006Journal of Cardiovascular Pharmacology and Therapeutics

The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease

View Full Paper
Ask AI
Bookmark
Share

Key result

Ex vivo treatment with AGI-1067 significantly inhibited ADP-induced platelet aggregation and decreased surface expression of major platelet receptors.

Why the study?

Does ex vivo AGI-1067 inhibit platelet aggregation and surface receptor expression in blood from aspirin-naïve volunteers with vascular risk factors?

Population

20 aspirin-naïve volunteers with multiple risk factors for vascular disease

Design

Preclinical

Authors

VSVictor L. SerebruanyAMAlex I. MalininRSRobert C. Scott

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for AGI-1067 antiplatelet effects; prospective trials needed before any clinical consideration.

Structured PICO

Does ex vivo AGI-1067 inhibit platelet aggregation and surface receptor expression in blood from aspirin-naïve volunteers with vascular risk factors?

P
Population
20 aspirin-naïve volunteers with multiple risk factors for vascular disease whose blood was evaluated for ex vivo platelet aggregation.
I
Intervention
Ex vivo preincubation of blood with escalating concentrations of AGI-1067
O
Outcome
Platelet aggregation (adenosine diphosphate-induced) and expression of major surface receptors (glycoprotein IIb/IIIa antigen, PAC-1 activity, and glycoprotein Ib/CD42b) evaluated by flow cytometrysurrogate

The novel antioxidant AGI-1067 demonstrates significant ex vivo antiplatelet activity by inhibiting ADP-induced aggregation and key surface receptors, suggesting potential as a therapeutic agent.

Limitations

  • These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant.
  • Ex vivo study design; data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant

Cite This Study

Serebruany et al. (2006) studied Multiple risk factors for vascular disease (n=20). AGI-1067 was evaluated on Platelet aggregation and expression of major surface receptors. Ex vivo treatment with AGI-1067 significantly inhibited ADP-induced platelet aggregation and decreased surface expression of major platelet receptors.

synapsesocial.com/papers/6a9750aacfa25b768ec60873https://doi.org/10.1177/1074248406290598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibitory Effect of Protocatechuic Acid on Platelet Aggregation Induced by High Shear Stress2020
  2. 2Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates1999 · 21 citations
  3. 3Pharmacological analysis of integrin function: Inhibition of vascular stenosis and identification of a novel antiplatelet substance.2000 · 1 citations
  4. 4Chlorogenic Acid Inhibits Human Platelet Activation and Thrombus Formation2014 · 127 citations
  5. 5Inhibition of Microsurgical Thrombosis by the Platelet Glycoprotein IIb/IIIa Antagonist SR121566A2003 · 16 citations